Neuren Pharmaceuticals(ASX:NEU)
Developing drug therapies forserious neurological disorders that emerge in early childhood &have no or limited treatment options
Highly successful US launchof DAYBUE™ (trofinetide) for Rett syndrome by partner Acadia
2023 net sales of US$177.2m;A$27m NEU royalties
1Q24 net sales US$75.9;A$11.6m royalties
2024 net sales guidance ofUS$370-420m; would earn NEU A$61-70m + A$77m sales milestone
Acadia advancingDAYBUE™ in Canada, Europe & Japan
NNZ-2591 in Phase 2 trialsfor four syndromes; 5x Rett market
All indications received FDAinvestigational new drug (IND) & orphan drug designation
Pitt Hopkins topline resultsexpected 2Q24, Angelman results expected 3Q24
Dec'23: PMS demonstratedsignificantly positive results, preparation underway for FDA end of Ph2 meeting
$243.1m cash as of 31 Mar'24
Market cap ~ $2.58B
- Forums
- ASX - By Stock
- Neuren Media and Analyst Coverage
Neuren Pharmaceuticals(ASX:NEU)Developing drug therapies...
-
- There are more pages in this discussion • 153 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$19.57 |
Change
-0.410(2.05%) |
Mkt cap ! $2.548B |
Open | High | Low | Value | Volume |
$19.92 | $20.04 | $19.51 | $1.869M | 94.11K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 50 | $19.56 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.58 | 44 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 591 | 19.500 |
3 | 274 | 19.490 |
2 | 230 | 19.480 |
2 | 224 | 19.470 |
2 | 231 | 19.460 |
Price($) | Vol. | No. |
---|---|---|
19.530 | 119 | 6 |
19.540 | 295 | 6 |
19.550 | 431 | 11 |
19.560 | 630 | 14 |
19.570 | 467 | 12 |
Last trade - 13.43pm 19/06/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
P.HOTC
HotCopper
Don Currie, CEO
Don Currie
CEO
Previous Video
Next Video
SPONSORED BY The Market Online